CLAIMS

1. A nucleic acid comprising a sense strand and an antisense strand, wherein the sense strand comprises a sequence having at least 80% sequence identity with a sequence as set forth in any one of SEQ ID NOs: 1 to 26, and the antisense strand comprises a sequence having at least 80% sequence identity with a sequence as set forth in any one of SEQ ID NOs: 27 to 52.

2. The nucleic acid according to claim 1, wherein the antisense strand comprises at least 15 consecutive nucleotides that differ from a sequence as set forth in any one of SEQ ID NOs: 27 to 52 by no more than 3 nucleotides, and the sense strand comprises a nucleotide sequence that is at least partially complementary to the antisense strand; and optionally, the sense strand comprises at least 15 consecutive nucleotides that differ from a sequence as set forth in any one of SEQ ID NOs: 1 to 26 by no more than 3 nucleotides.

3. The nucleic acid according to claim 1, wherein the antisense strand comprises a nucleotide sequence that differs from a sequence as set forth in any one of SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, or SEQ ID NO: 44, preferably from a sequence as set forth in any one of SEQ ID NO: 29, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 43, or SEQ ID NO: 44, and more preferably from a sequence as set forth in SEQ ID NO: 40, by 0, 1, or 2 nucleotides, and the sense strand comprises a nucleotide sequence that is at least partially complementary to the antisense strand; and optionally, the sense strand comprises a nucleotide sequence that differs from a sequence as set forth in any one of SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 18, preferably from a sequence as set forth in any one of SEQ ID NO: 3, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 18, and more preferably from a sequence as set forth in SEQ ID NO: 14, by 0, 1, or 2 nucleotides.

4. The nucleic acid according to claim 1, wherein a content of GC in the nucleic acid is 20%-45%, preferably 20%-35%.

5. The nucleic acid according to claim 1, wherein at least one nucleotide in the nucleic acid is a modified nucleotide or comprises a modified internucleotide linkage;

the modified nucleotide is preferably one or more selected from the group consisting of 2'-O-methyl nucleotide, 2'-fluoro nucleotide, 2'-deoxy nucleotide, 2',3'-seco nucleotide mimetic, locked nucleotide, 2'-F-arabinonucleotide, 2'-methoxyethyl nucleotide, abasic nucleotide, ribitol, inverted nucleotide, inverted 2'-O-methyl nucleotide, inverted 2'-deoxy nucleotide, 2'-

amino modified nucleotide, 2'-alkyl modified nucleotide, morpholino nucleotide, nucleotide containing vinyl phosphonate, nucleotide containing cyclopropyl phosphonate, and 3'-O-methyl nucleotide; and the modified nucleotide is more preferably one or more selected from the group consisting of 2'-O-methyl nucleotide and 2'-fluoro nucleotide; and

the modified internucleotide linkage is preferably one or more selected from the group consisting of phosphorothioate internucleotide linkage and methylphosphonate internucleotide linkage; and the modified internucleotide linkage is more preferably one or more selected from the group consisting of phosphorothioate monoester internucleotide linkage and phosphorothioate diester internucleotide linkage.

6. The nucleic acid according to claim 5, wherein, counted from the 5' end of the antisense strand, nucleotides at positions 5 and 6 are 2'-O-methyl nucleotides, and the nucleotide at position 7 is a 2'-fluoro nucleotide; and

preferably, each of the 5' end and 3' end of the antisense strand contains two phosphorothioate internucleotide linkages, nucleotides at positions 1, 2, 7, 9, 14, and 16, counted from the 5' end, are 2'-fluoro nucleotides, and all of the remaining nucleotides are 2'-O-methyl nucleotides.

7. The nucleic acid according to claim 5 or 6, wherein the nucleotide at position 2, counted from the 5' end of the sense strand, is a 2'-O-methyl nucleotide or a 2'-fluoro nucleotide, preferably a 2'-O-methyl nucleotide; and

preferably, the 5' end of the sense strand contains two phosphorothioate internucleotide linkages, nucleotides at positions 4, 7, 9, 10, and 11, counted from the 5' end, are 2'-fluoro nucleotides, and all of the remaining nucleotides are 2'-O-methyl nucleotides.

8. The nucleic acid according to claim 1, wherein the antisense strand has at least 15 consecutive nucleotides that differ from any one of antisense strand sequences shown in Table 3 or Table 8 by no more than 3 nucleotides, the sense strand has at least 15 consecutive nucleotides that differ from any one of sense strand sequences shown in Table 3 or Table 8 by no more than 3 nucleotides; and preferably, the sense strand and the antisense strand form any one of siRNAs shown in Table 4 or Table 8.

Table 3

No.	Sense strand (5'-3')	No.	Antisense strand (5'-3')
SN-22158	cscsacgcUfcUfCfUfggacuucaca	SN-52158	usGfsuGfaAfguccaGfaGfagcguggsgsa
SN-22159	usgsgacaAfcAfGfCfaccucagugu	SN-52159	asCfsaCfuGfaggugcuGfuUfguccasusu
SN-22160	gsuscucaCfuUfUfCfcagcaaaacu	SN-52160	asGfsuUfuUfgcuggaaAfgUfgagacsusu
SN-22161	cscsucaaCfuGfGfAfugaagaaacu	SN-52161	asGfsuUfuCfuucauccAfgUfugaggsgsa

SN-22163	ususccugUfuUfGfCfuguguaugau	SN-52163	asUfscAfuAfcacagcaAfaCfaggaasusg
SN-22164	gscsugggUfuUfAfUfuuuagagaau	SN-52164	asUfsuCfuCfuaaaauaAfaCfccagcsusu
SN-22165	csusggguUfuAfUfUfuuagagaaug	SN-52165	csAfsuUfcUfcuaaaauAfaAfcccagsusu
SN-22166	cscsaaccGfaCfCfAfgcuuguuugu	SN-52166	asCfsaAfaCfaagcuggUfcGfguuggsasa
SN-22167	cscsgaccAfgCfUfUfguuugugaaa	SN-52167	usUfsuCfaCfaaacaagCfuGfgucggsusu
SN-22168	gsasccagCfuUfGfUfuugugaaaca	SN-52168	usGfsuUfuCfacaaacaAfgCfuggucsgsg
SN-22169	gsasccagCfuUfGfUfuugugaaaca	SN-52169	usGfsuUfuCfacaaacaAfgCfuggucsusu
SN-22170	cscsagcuUfgUfUfUfgugaaacaaa	SN-52170	usUfsuGfuUfucacaaaCfaAfgcuggsusc
SN-22171	gscsuuguUfuGfUfGfaaacaaaaaa	SN-52171	usUfsuUfuUfguuucacAfaAfcaagcsusg
SN-22172	gsusuuguGfaAfAfCfaaaaaagugu	SN-52172	asCfsaCfuUfuuuguuUfcAfcaaacsasa
SN-22173	csasaaaaAfgUfGfUfucccuuuuca	SN-52173	usGfsaAfaAfgggaacaCfuUfuuuugsusu
SN-22174	cscscuuuUfcAfAfGfuugagaacaa	SN-52174	usUfsgUfuCfucaacuuGfaAfaagggsusu
SN-22175	gsasgaacAfaAfAfAfuuggguuuua	SN-52175	usAfsaAfaCfccaauuuUfuGfuucucsasa
SN-22176	gsasacaaAfaAfUfUfgggguuuuaaa	SN-52176	usUfsuAfaAfacccaauUfuUfuguucsusc
SN-22177	gscsauugCfcUfUfCfgguuuguauu	SN-52177	asAfsuAfcAfaaccgaaGfgCfaaugcsasa
SN-22178	csasuugcCfuUfCfGfguuuguauuu	SN-52178	asAfsaUfaCfaaaccgaAfgGfcaaugscsa
SN-22179	cscsuucgGfuUfUfGfuauuuagugu	SN-52179	asCfsaCfuAfaauacaaAfcCfgaaggscsa
SN-22180	gsgsuuugUfaUfUfUfagugucuuga	SN-52180	usCfsaAfgAfcacuaaaUfaCfaaaccsgsa
SN-22181	gsusauuuAfgUfGfUfcuugaaugua	SN-52181	usAfscAfuUfcaagacaCfuAfaauacsusu
SN-22182	gsusgucuUfgAfAfUfguaagaacau	SN-52182	asUfsgUfuCfuuacauuCfaAfgacacsusu
SN-22183	gsuscuugAfaUfGfUfaagaacauga	SN-52183	usCfsaUfgUfucuuacaUfuCfaagacsasc
SN-22184	cscsauagCfuGfGfUfuauuucuccu	SN-52184	asGfsgAfgAfaauaaccAfgCfuauggsusu

Table 4

No.	Sense strand (5'-3')	Antisense strand (5'-3')
SN-252158	cscsacgcUfcUfCfUfggacuucaca	usGfsuGfaAfguccaGfaGfagcguggsgsa
SN-252159	usgsgacaAfcAfGfCfaccucagugu	asCfsaCfuGfaggugcuGfuUfguccasusu
SN-252160	gsuscucaCfuUfUfCfcagcaaaacu	asGfsuUfuUfgcuggaaAfgUfgagacsusu
SN-252161	cscsucaaCfuGfGfAfugaagaaacu	asGfsuUfuCfuucauccAfgUfugaggsgsa
SN-252163	ususccugUfuUfGfCfuguguaugau	asUfscAfuAfcacagcaAfaCfaggaasusg
SN-252164	gscsugggUfuUfAfUfuuuagagaau	asUfsuCfuCfuaaaauaAfaCfccagcsusu
SN-252165	csusggguUfuAfUfUfuuagagaaug	csAfsuUfcUfcuaaaauAfaAfcccagsusu
SN-252166	cscsaaccGfaCfCfAfgcuuguuugu	asCfsaAfaCfaagcuggUfcGfguuggsasa
SN-252167	cscsgaccAfgCfUfUfguuugugaaa	usUfsuCfaCfaaacaagCfuGfgucggsusu
SN-252168	gsasccagCfuUfGfUfuugugaaaca	usGfsuUfuCfacaaacaAfgCfuggucsgsg
SN-252169	gsasccagCfuUfGfUfuugugaaaca	usGfsuUfuCfacaaacaAfgCfuggucsusu
SN-252170	cscsagcuUfgUfUfUfgugaaacaaa	usUfsuGfuUfucacaaaCfaAfgcuggsusc
SN-252171	gscsuuguUfuGfUfGfaaacaaaaaa	usUfsuUfuUfguuucacAfaAfcaagcsusg
SN-252172	gsusuuguGfaAfAfCfaaaaaagugu	asCfsaCfuUfuuuguuUfcAfcaaacsasa
SN-252173	csasaaaaAfgUfGfUfucccuuuuca	usGfsaAfaAfgggaacaCfuUfuuuugsusu
SN-252174	cscscuuuUfcAfAfGfuugagaacaa	usUfsgUfuCfucaacuuGfaAfaagggsusu
SN-252175	gsasgaacAfaAfAfAfuuggguuuua	usAfsaAfaCfccaauuuUfuGfuucucsasa
SN-252176	gsasacaaAfaAfUfUfgggguuuuaaa	usUfsuAfaAfacccaauUfuUfuguucsusc
SN-252177	gscsauugCfcUfUfCfgguuuguauu	asAfsuAfcAfaaccgaaGfgCfaaugcsasa
SN-252178	csasuugcCfuUfCfGfguuuguauuu	asAfsaUfaCfaaaccgaAfgGfcaaugscsa
SN-252179	cscsuucgGfuUfUfGfuauuuagugu	asCfsaCfuAfaauacaaAfcCfgaaggscsa
SN-252180	gsgsuuugUfaUfUfUfagugucuuga	usCfsaAfgAfcacuaaaUfaCfaaaccsgsa

SN-252181	gsusauuuAfgUfGfUfcuugaaugua	usAfscAfuUfcaagacaCfuAfaauacsusu
SN-252182	gsusgucuUfgAfAfUfguaagaacau	asUfsgUfuCfuuacauuCfaAfgacacsusu
SN-252183	gsuscuugAfaUfGfUfaagaacauga	usCfsaUfgUfucuuacaUfuCfaagacsasc
SN-252184	cscsauagCfuGfGfUfuauuucuccu	asGfsgAfgAfaauaaccAfgCfuauggsusu

Table 8

Number of siRNA	Sense strand	Antisense strand
SN-682725	gsusuUfguGfaAfAfCfaaaaaagugu-TrigalNac	AfsCfsacuUfuuUfuguuUfcAfcaaacsasa
SN-682726	gsusuUfguGfaAfAfCfaaaaaagugu-TrigalNac	AfsCfsacuuUfuUfuguuUfcAfcaaacsasa
SN-682727	gsUfsuUfguGfaAfAfCfaaaaaagugu-TrigalNac	AfsCfsacuUfuuUfuguuUfcAfcaaacsasa
SN-682728	gsUfsuUfguGfaAfAfCfaaaaaagugu-TrigalNac	AfsCfsacuuUfuUfuguuUfcAfcaaacsasa
SN-682172	gsusuuguGfaAfAfCfaaaaaagugu-TrigalNac	asCfsaCfuUfuuuuguuUfcAfcaaacsasa

9. The nucleic acid according to claim 1, wherein the antisense strand comprises, from the 5' end to the 3' end, a nucleotide sequence that differs from the following nucleotide sequence by 0, 1, or 2 nucleotides:

AfsCfsacuuUfuUfuguuUfcAfcaaacsasa;

the sense strand comprises a nucleotide sequence that is at least partially complementary to the antisense strand; and

preferably, the sense strand comprises, from the 5' end to the 3' end, a nucleotide sequence that differs from any one of the following nucleotide sequences by 0, 1, or 2 nucleotides:


gsusuUfguGfaAfAfCfaaaaaagugu; or

gsUfsuUfguGfaAfAfCfaaaaaagugu;

wherein in each sequence, a nucleotide represented by a lowercase letter is 2'-O-methyl nucleotide; "f" indicates that an adjacent nucleotide on the left side is a nucleotide modified by 2'-fluoro; and "s" indicates that two adjacent nucleotides on the left and right sides are linked by a phosphorothioate diester bond.

10. A targeted drug delivery system, wherein the targeted drug delivery system comprises a targeting moiety, a linking moiety, and the nucleic acid according to any one of claims 1 to 9 that is linked to the targeting moiety through the linking moiety.

11. The targeted drug delivery system according to claim 10, wherein the targeted drug delivery system comprises a ligand and the nucleic acid linked to the ligand; preferably, the ligand is a GalNAc derivative; more preferably, the ligand is one or more GalNAc derivatives linked via a single-stranded, double-stranded or triple-stranded branched linker; and even more preferably, a structure of the targeted drug delivery system is represented by a formula of



in which Nu represents the nucleic acid.

12. A pharmaceutical composition, wherein the pharmaceutical composition comprises the nucleic acid according to any one of claims 1 to 9, or the targeted drug delivery system according to any one of claims 10 to 11, and a pharmaceutically acceptable carrier.

13. The nucleic acid according to any one of claims 1 to 9, the targeted drug delivery system according to any one of claims 10 to 11, or the pharmaceutical composition according to claim 12, for use in any one of the following aspects:

1) in the treatment and/or prevention of a disease associated with angiotensin; or

2) as a medicament for treating and/or preventing a disease associated with angiotensin.

14. The nucleic acid, targeted drug delivery system, or pharmaceutical composition for use according to claim 13, wherein the disease is:

i) a disease associated with enhancement or elevation of an activity level of angiotensin; or

ii) a disease that benefits from reduced expression of angiotensinogen; or

iii) a disease associated with excessive activation of a renin-angiotensin-aldosterone system;

wherein preferably the disease is one or more selected from the group consisting of hypertension, hypertensive disorder, borderline hypertensive disorder, primary hypertensive disorder, secondary hypertensive disorder, isolated systolic or diastolic hypertensive disorder, pregnancy-related hypertensive disorder, diabetic hypertensive disorder, resistant hypertensive disorder, refractory hypertensive disorder, paroxysmal hypertensive disorder, renovascular hypertensive disorder, Goldblatt hypertension, hypertensive disorder associated with low plasma renin activity or plasma renin concentration, high intraocular pressure, glaucoma, pulmonary arterial hypertension, portal hypertension, systemic venous hypertension, systolic

hypertensive disorder, unstable hypertensive disorder; hypertensive heart disease, hypertensive nephropathy, atherosclerosis, arteriosclerosis, vascular disease, diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiomyopathy, glomerulosclerosis, coarctation of the aorta, aortic aneurysm, ventricular fibrosis, heart failure, myocardial infarction, angina pectoris, stroke, nephropathy, renal failure, systemic sclerosis, intrauterine growth restriction, fetal growth restriction, obesity, hepatic steatosis/fatty liver, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, glucose intolerance, type 2 diabetes mellitus, and metabolic syndrome.

15. The nucleic acid, targeted drug delivery system, or pharmaceutical composition for use according to claim 13, wherein the nucleic acid, the targeted drug delivery system, or the pharmaceutical composition is to be administered to a subject via subcutaneous administration, intravenous administration, and/or intramuscular administration.